Cancer Risk in Children and Adults With Eczema: A U.K. Cohort

Evidence in one sentence: Overall malignancy risk was not materially different, while severe eczema was associated with higher lymphoma estimates and skin-cancer findings varied by age and severity. This is a finding from a population-based matched cohort study, not proof that eczema or an eczema medicine caused cancer. [1]

Why this study matters. Questions about eczema and malignancy are emotionally charged because both the disease and its treatments can be long term. The useful question is not whether a relative estimate is above or below one in isolation. It is whether the study measured comparable people, established the correct time order, handled severity and treatment fairly, and translated a rare outcome into an understandable absolute risk. This review examines overall and site-specific malignancy risk across eczema severity in children and adults while keeping those distinctions visible. [2]

Study design and population

The investigators used a population-based matched cohort study involving 409,431 children and 625,083 adults with atopic dermatitis plus matched controls. That design can be valuable for identifying uncommon outcomes and evaluating real-world patterns beyond the narrow eligibility criteria of clinical trials. It also inherits the limitations of the source data: a diagnosis code may not capture morphology, pathology confirmation, treatment adherence, cumulative exposure or the clinical reasoning that led to a referral. [3]

The central analytic challenge is eczema severity, cancer ascertainment and the difference between relative and absolute risk. A large number of records can narrow random error, but it does not automatically remove systematic error. Matching or multivariable adjustment balances only the variables that were collected and modeled adequately. Unrecorded ultraviolet exposure, family cancer history, smoking intensity, prior immune-modifying treatment and frequency of skin examination may still matter. [4]

What the researchers reported

Overall malignancy risk was not materially different, while severe eczema was associated with higher lymphoma estimates and skin-cancer findings varied by age and severity. The wording is important: “associated with,” “observed,” or “estimated” is more accurate than “caused.” The study result should be read alongside its confidence interval, the number of events, follow-up time, comparator definition and any subgroup analysis. A statistically compatible association may still represent a small absolute difference; a null estimate may still be too imprecise to exclude a clinically meaningful effect. [5]

Subgroup findings by severity, age, sex, treatment, latency or cancer subtype are usually less precise than the main analysis. They can be informative when prespecified and biologically coherent, but repeated comparisons increase the chance of an apparently notable result. Replication across independent datasets and methods is more persuasive than one isolated subgroup. [6]

Relative risk is not absolute risk

A relative estimate compares rates between groups. It does not tell a reader how many additional cases occurred per thousand or ten thousand people over a defined period. When the baseline event is rare, a seemingly large relative difference may correspond to a small absolute difference. Conversely, a modest relative difference can matter for a common outcome. Good counseling uses both scales and states the follow-up window. [7]

Absolute risk also changes with age, prior cancer, immune status, ultraviolet exposure, smoking and other factors. The average estimate from this study is not a personalized prediction. A clinician may reasonably interpret the same population result differently for a healthy child, an older adult with extensive sun damage, and a person with prior lymphoma. [8]

Biases that can imitate a cancer signal

The exposure here is eczema or an eczema-related clinical history, not a randomized treatment assignment. Differences in care-seeking, referral and diagnostic intensity can influence which cancers are discovered and when. [9]

Population studies can estimate patterns across large groups, yet they cannot show that eczema biologically caused a cancer. Severe disease, smoking, obesity, immune conditions, ultraviolet exposure, socioeconomic factors, health-care contact and prescription history can cluster together. Even extensive statistical adjustment leaves room for unmeasured or imperfectly measured confounding. [10]

Reverse causation is another concern. Early systemic effects of an undiagnosed cancer may change immunity, produce itching, alter health-care use or prompt a dermatitis diagnosis. Lag analyses that exclude cancers detected soon after eczema or treatment initiation can help, but they cannot remove every preclinical case or prove a mechanism. [11]

What this evidence does not establish

The study does not establish that eczema transforms into cancer. It does not show that stopping prescribed treatment lowers cancer risk, and it does not justify avoiding effective eczema care. It also cannot prove that a treatment is risk-free for every person. Observational estimates, trials, registries, pathology review, pharmacovigilance and mechanistic work answer different parts of the safety question. [12]

The authors’ major limitations include treatment and referral proxies for severity, coding, surveillance differences, residual confounding, rare-event imprecision and possible diagnostic overlap with cutaneous lymphoma. These are not technical footnotes. Each one can move an estimate toward or away from an association. A careful interpretation asks how large that movement could plausibly be and whether results remained consistent in sensitivity analyses. [13]

Clinical context without alarm

Most people with eczema will not develop the cancers discussed in these studies. Routine eczema care should continue to focus on an accurate diagnosis, skin-barrier support, control of inflammation, infection recognition and shared decisions about prescription therapy. Cancer screening should follow age-, risk- and jurisdiction-appropriate recommendations unless a clinician identifies a reason for additional evaluation. [14]

Seek timely medical assessment for persistent enlarged lymph nodes, unexplained weight loss, drenching night sweats, prolonged fever, unusual bruising, or a rash that changes substantially. These findings often have noncancer explanations, but persistence or change deserves examination. Rapidly worsening illness, breathing difficulty, facial swelling, widespread blistering, eye involvement, high fever, severe pain or signs of serious infection require urgent care. [15]

For infants and children, the study should not be used to label future cancer risk or to change treatment without the child’s clinician. Growth, infection, vaccination, treatment exposure and age-appropriate examination all need separate consideration. Pregnancy, breastfeeding, prior malignancy, immune compromise and concurrent immune-modifying medicines also require individualized prescribing discussion; a blog cannot substitute for that review. [16]

How to use the finding in a treatment decision

Do not start, stop, taper or substitute a prescription because of this article. Ask the prescriber about the expected benefit, approved age and body-surface limits, monitoring, infection precautions, vaccination timing, pregnancy plans, previous cancer and reasonable alternatives. The most appropriate option depends on disease severity, prior response, comorbidities and patient preferences—not on a headline alone. [17]

When comparing evidence, prioritize a prespecified comparator, validated outcome definitions, adequate latency, transparent event counts and adjustment for disease severity and prior treatment. For rare cancers, pooled or registry evidence may be needed, but pooling does not correct a shared bias across component studies. Concordance among several designs is more reassuring than precision from one database.

Practical questions for the next appointment

• Was the original eczema diagnosis secure, and has the rash’s pattern changed?
• What was the absolute event rate, not only the relative estimate?
• Were cancers pathology-confirmed or identified only from codes?
• How did the study handle disease severity, prior treatment and medical-contact frequency?
• Does the evidence apply to this age, dose, duration and health history?
• What symptoms or examination findings should prompt reassessment?
• What monitoring is recommended by the current label and clinical guideline?

Related Dr. Arsy evidence reviews

• Topical calcineurin inhibitors and cancer-risk evidence
• How to interpret eczema and lymphoma absolute risk
• Changing rashes, dupilumab and CTCL diagnostic questions
• Long-term pediatric tacrolimus cancer surveillance
• UVB phototherapy and skin-cancer cohort evidence
• Autoimmune diagnoses after eczema
• Patch testing during dupilumab treatment
• Five-year dupilumab laboratory follow-up

Where Dr. Arsy #003 fits—and does not fit

Dr. Arsy Moisturizer #003 is a cosmetic moisturizer for dry, sensitive and eczema-prone skin. It was not the study product, exposure, medicine or intervention in this research. #003 does not treat, cure or prevent eczema, lymphoma, skin cancer or any other malignancy, and findings about prescription medicines, phototherapy, immune pathways or cancer outcomes must not be transferred to it.

A moisturizer may be used as part of ordinary skin-comfort and moisture-barrier care when appropriate, but it cannot diagnose a changing eruption or replace clinician-directed evaluation and treatment. Patch-test a new cosmetic when practical, stop if significant irritation occurs, and seek care for infection, widespread blistering, eye involvement or systemic illness.

Bottom line

This population-based matched cohort study adds evidence about overall and site-specific malignancy risk across eczema severity in children and adults. Its most defensible message is Overall malignancy risk was not materially different, while severe eczema was associated with higher lymphoma estimates and skin-cancer findings varied by age and severity. The result should be interpreted through absolute event rates, latency, comparator quality, diagnostic certainty and the limitations above. It supports informed surveillance and shared decision-making—not fear, self-diagnosis or unsupervised treatment changes.

References

1. Cancer Risk in Children and Adults With Eczema: A U.K. Cohort. PubMed PMID 37418646.
2. Eczema and Cancer in England and Denmark: Two Large Cohorts. PubMed PMID 32579178.
3. Eczema and Cancer Across 56 Observational Studies. PubMed PMID 31825457.
4. Lymphoma Risk in Eczema: A 13-Study Meta-Analysis. PubMed PMID 40297814.
5. Malignancy Rates in 7,050 Adults With Moderate-to-Severe Eczema. PubMed PMID 36898743.
6. Nonmelanoma Skin Cancer in 391,753 U.S. Adults With Eczema. PubMed PMID 41082088.
7. Hodgkin Lymphoma Within 71 Eczema Outcomes in U.K. Primary Care. PubMed PMID 39505873.
8. Eczema, Lymphoma and Dupilumab in a Large TriNetX Cohort. PubMed PMID 41641262.
9. Malignancy in 11 Trials of Advanced Eczema Therapies. PubMed PMID 39027698.
10. Targeted Eczema Therapy When Cancer Is Current or Previous. PubMed PMID 42573454.
11. Dupilumab and Cutaneous T-Cell Lymphoma in a TriNetX Cohort. PubMed PMID 38588818.
12. Dupilumab and CTCL: 51 Studies, 547 Patients and Expert Consensus. PubMed PMID 41821352.
13. EORTC Guidance When Cutaneous Lymphoma Is Suspected During Dupilumab. PubMed PMID 41967816.
14. Topical Calcineurin Inhibitors and Cancer in 66,176 Eczema Patients. PubMed PMID 27049893.
15. Topical Calcineurin Inhibitors and Lymphoma in FAERS, 2014–2025. PubMed PMID 41969290.
16. Dupilumab and Cutaneous T-Cell Lymphoma: A Systematic Review. PubMed PMID 39992210.
17. Cancer Risk in 195,925 Taiwanese Eczema Patients Using Topical Therapy. PubMed PMID 37280416.
18. American Academy of Dermatology atopic dermatitis clinical guidelines.
19. National Cancer Institute: What Is Cancer?.
20. U.S. FDA: pimecrolimus and tacrolimus safety information.
21. National Cancer Institute: Mycosis fungoides and Sézary syndrome treatment information.